Catalyst Alleges US FDA 'Facilitating' Off-Label Use With Jacobus' Ruzurgi Approval

 
• By Derrick Gingery
Firdapse and Ruzurgi both received orphan drug designations, which made Ruzurgi's approval complicated since it came after Firdapse. • Source: Shutterstock

More from Legal & IP

More from Pink Sheet